Moderator: Axel Ferrazzini

October 30, 2022

Axel is the managing director of 4iP Council since 2017, a European research council working across a broad variety of industries and sectors to promote the role of intellectual property in innovation. He has a strong background in technology research and policy development. In addition to be an elected member of the ETSI Board since 2014, Axel’s career is rooted in research and development and holds more than 20 patents. He has been selected in the 2022 edition of IAM Strategy 300: The World’s Leading IP Strategists.

Axel has an MS in Computer Science from EPITA and an Executive MBA in innovation strategy and entrepreneurship from the ESSEC & Mannheim business schools.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor